8-K filing — Vivos Therapeutics, Inc. (VVOS)
Filed: 2026-08-21 AccNo: 0001493152-26-039736 Size: 224 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarStocks · News reference
Vivos Therapeutics Announces 212% Rise YoY Over Most Recent Six-Week Period In Its New Obstructive Sleep Apnea Patient Referrals At Its Nevada Sleep & Airway Medicine Centers
Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ:VVOS), a leading medical device and healthcare services company focused on developing and commercializing innovative diagnostic and treatment
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 25, 2026, 12:47 PM
- Checked
- Aug 25, 2026, 12:47 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Picard Medical (AMEX:PMI) stock rose 40.2% to $4.5 during Friday's after-market session. The company's market cap stands at $6.2 million. As per the news, the Q2 earnings report came out 2 days ago.
Read original at benzingaVivos Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript
Vivos Therapeutics (NASDAQ:VVOS) held its second-quarter earnings conference call on Friday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive financial data and
Read original at benzinga